Cooper, C., Naggie, S., Saag, M., Yang, J., Stamm, L., Pang, P., … Sulkowski, M. (2015). P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study. In Journal of Hepatology (Vol. 62, pp. S675–S676). Elsevier BV. https://doi.org/10.1016/s0168-8278(15)31090-4

Cooper, C., S. Naggie, M. Saag, J. Yang, L. Stamm, P. Pang, J. McHutchison, D. Dieterich, and M. Sulkowski. “P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study.” In Journal of Hepatology, 62:S675–76. Elsevier BV, 2015. https://doi.org/10.1016/s0168-8278(15)31090-4.

Cooper C, Naggie S, Saag M, Yang J, Stamm L, Pang P, et al. P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study. In: Journal of Hepatology. Elsevier BV; 2015. p. S675–6.

Cooper, C., et al. “P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study.” Journal of Hepatology, vol. 62, Elsevier BV, 2015, pp. S675–76. Crossref, doi:10.1016/s0168-8278(15)31090-4.

Cooper C, Naggie S, Saag M, Yang J, Stamm L, Pang P, McHutchison J, Dieterich D, Sulkowski M. P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study. Journal of Hepatology. Elsevier BV; 2015. p. S675–S676.